CN104707101A - Liver cancer and lung cancer resistant traditional Chinese medicine composition and application thereof - Google Patents
Liver cancer and lung cancer resistant traditional Chinese medicine composition and application thereof Download PDFInfo
- Publication number
- CN104707101A CN104707101A CN201510088489.7A CN201510088489A CN104707101A CN 104707101 A CN104707101 A CN 104707101A CN 201510088489 A CN201510088489 A CN 201510088489A CN 104707101 A CN104707101 A CN 104707101A
- Authority
- CN
- China
- Prior art keywords
- extract
- chinese medicine
- medicine composition
- radix bupleuri
- crude drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a liver cancer and lung cancer resistant traditional Chinese medicine composition which comprises a radix bupleuri extract, a turmeric extract and a rhizoma anemarrhenae extract in a mass ratio of (1-10): 1: (1-10). In-vitro experiments prove that the composition has the advantage of remarkably inhibiting the growth of lung cancer cell strains and liver cancer cell strains and the IC50 is 20 mg/mL or below (crude drug dosage); and in-vivo experiments prove that the composition has the advantages of inhibiting the growth of liver cancer and osteosarcoma, improving the immunologic function index, prolonging the Ehrlich ascites tumor (EAC) animal survival time and being relatively low in toxic and side effects. The traditional Chinese medicine composition provided by the invention is reasonable in compatibility of medicines and remarkable in curative effect and none of the three extracts can be omitted. Therefore, the liver cancer and lung cancer resistant traditional Chinese medicine composition has development potential.
Description
Technical field
The present invention relates to the Chinese medicine composition of a kind of anti-hepatocarcinoma and pulmonary carcinoma, belong to technical field of Chinese medicines.
Background technology
WHO Report claims, and cancer has surmounted the number one killer that heart disease becomes harm humans life and health.In recent years, in the world, newly-increased cases of cancer and cancer death lead with the speed increase of annual 1%, and the speed that these countries of China, Russia and India increase is faster.Therefore prevention and therapy cancer is a great problem of 21 century facing mankind.The development and investigation of antitumor drug becomes the important topic of pharmaceutical researchers in recent years.There is toxic and side effects greatly in the chemotherapeutic of Therapeutic cancer, the deficiency of somewhat expensive, the choice drug of current many treatment tumors derives from plant, as paclitaxel, camptothecine, vincristine etc.Treatment by Chinese herbs disease emphasizes dialectical treatmert and wholistic therapy, multicomponent Mutiple Targets Therapeutic cancer, so from theory of Chinese medical science, filters out the focus that the unique antitumor drug of effect and antitumour auxiliary drug become Present Domestic Chinese medicine study in Chinese herbal medicine.
Radix Bupleuri begins to be loaded in Shennong's Herbal, and be classified as top grade, be traditional conventional Chinese medicine, applicating history is long, and medicinal part is root, has the effects such as evacuation is brought down a fever, soothing the liver, yang invigorating.Cure mainly the diseases such as flu, heating, alternate attack of chill and fever, feeling of fullness and disecomfort in the chest and hypochondrium.Radix Bupleuri contains number of chemical composition, has reported up to now containing compositions such as saponin, lignanoid, flavone, volatile oil, coumarin, sterol, organic acid, polysaccharide and polyacetylene classes.Modern pharmacology experiment proves that Radix Bupleuri has antipyretic, antiinflammatory, calmness, protects the liver, reduces blood pressure, slows down the multiple biological activitys such as heart rate.Saikoside has antiinflammatory, anti-experimental character hepatic injury, antitumor, endocrine regulation and immune function.Saikoside a, b, c, d were isolated at first in 1966 in Kubo field etc. from Bupleurum falcatum.Song Jinggui etc. report that Radix Bupleuri extract is active to human hepatocarcinoma BEL-7402 Metabolism of Mitochondria, and cell proliferation and mice transplant S180 entity tumor obvious inhibitory action.Wang Yanli etc. report that saikoside a can make the syngignoscism of cyclobarbital extend, prove that saikoside may make liver drug metabolism enzyme system be suppressed, prevent the metabolism of cancer therapy drug in liver with killer cell effect, drugs against tumor effect is strengthened.Yang Huiling etc. report that Herba Sidae Rhombifoliae soup has obvious inhibitory action to mice with tumor S180, inhibitory rate 40.19% ~ 58.73%.Li Jiang etc. report that Herba Sidae Rhombifoliae soup water extraction group, graded ethanol group and alcohol water group all have obvious inhibitory action to H22 rat liver cancer solid tumor, tumour inhibiting rate difference 32.35%, 43.97% and 25.77%.Disclose one in Chinese patent CN1706454 and there is Radix Bupleuri and the synergistic anticancer pharmaceutical composition of polymycin.
Rhizoma Curcumae Longae begins to be loaded in Tang Materia Medica, for the dry rhizome of zingiberaceous plant Rhizoma Curcumae Longae Curcuma longa L., its nature and flavor acrid, bitter, warm, returns spleen, Liver Channel, there is removing blood stasis circulation of qi promoting, effect of inducing menstruation to relieve menalgia, can be used for the twinge of the breast side of body, obstruction of qi in the chest and cardialgia, dysmenorrhea amenorrhea mass in the abdomen, rheumatism shoulder arm pain, the treatment of the diseases such as tumbling and swelling.Rhizoma Curcumae Longae contains number of chemical composition, and main component is curcumin chemical compounds: curcumin, bisdemethoxycurcumin, demethoxycurcumin, dihydro curcumin etc.; Sesquiterpenoids: the new ketone of Rhizoma Curcumae Longae, Rhizoma Curcumae Longae keto-alcohol A, B etc.; Volatile oil (4.2%): turmerone, curcumene, curcumenol etc.The pharmacological action of the effective ingredient such as curcumin is extensive, the effect such as its antiinflammatory, antioxidation, atherosclerosis, antidepressant, antitumor has been commonly recognized, after wherein antitumor action proposed first from 1985, existing a large amount of experimentatioies confirms, mechanism of action mainly comprises inducing apoptosis of tumour cell, inhibiting angiogenesis, arresting cell cycle progression and reversing multiple medicine resistance of tumor cells etc.Huang Dongsheng etc. study discovery, and curcumin can strengthen the expression of Caspase-8, thus start exogenous apoptosis pathway, induction human lung carcinoma cell apoptosis.Fang Yue etc. report that curcumin has the effect of the digestive system tumors such as anti-esophageal carcinoma, gastric cancer, hepatocarcinoma, colon cancer.Chinese patent CN1931353A discloses curcumin and extracts and pharmaceutical composition preparation method.
The Rhizoma Anemarrhenae comes from Shennong's Herbal, is the dry rhizome of the monocotyledon Liliaceae Rhizoma Anemarrhenae, is famous Chinese medicine.Its property is bitter, sweet, cold, returns lung, stomach, kidney channel, has nourishing YIN to lower pathogenic fire, moisturizes laxation, the effect of sharp defecation.Can be used for fever caused by exogenous pathogenic factors, high hot excessive thirst, lung-heat type cough, osteopyrexia and fever, the diseases such as interior-heat is quenched one's thirst, dryness of the intestine constipation.Show through modern Natural Medicine Chemistry and pharmaceutical research, containing steroidal saponin, flavone, lignanoid, polysaccharide, sterol and fatty wet goods in the Rhizoma Anemarrhenae, wherein saponin is its main component.The fields such as defying age (Chinonin), antidepressant (Rhizoma Anemarrhenae total saponins), treatment Alzheimer (timosaponin Q), anti-type-II diabetes (chimonin) were substantially all concentrated on to the pharmacology activity research of the Rhizoma Anemarrhenae in the past and at present; what play is substantially all Cell protection or the effect promoting cell proliferation, but little in the research of anti-tumor aspect.Wang Lijuan etc. find that the diosgenin in the Rhizoma Anemarrhenae has significant inhibitory action to sarcoma, ascitic type liver cancer and cervical cancer etc. in Mice Body, also have obvious inhibitory action in vitro to mouse lung epithelial cancer cells, human cervical carcinoma cell and human breast cancer cell etc.Sy etc. find that HHG-001 has the effect bringing out Hela apoptosis of tumor cells, and find that the sugar chain of HHG-001 is active key structure, and its parent nucleus Sarsasapogenin does not have corresponding activity.In Chinese patent CN103599122A, disclose timosaponin in the Rhizoma Anemarrhenae prepare the application of antitumor drug.
Radix Bupleuri is antipyretic and antidotal type medicine, wherein contained saikoside a and saikoside d, there is obvious antitumor action, be used alone the tumor growth that described Radix Bupleuri extract can suppress tumor-bearing mice, but the weight of animals increase can be caused to slow down, present certain toxic and side effects, after compatibility Rhizoma Curcumae Longae and Rhizoma Anemarrhenae extract, it is normal that the weight of animals increases recovery, and tumor control rate significantly improves.Chinese prescription compatibility needs the support of theory of Chinese medical science and the checking of therapeutic effect, and compositions Radix Bupleuri of the present invention is pungent, bitter, be slightly cold, and the Rhizoma Anemarrhenae is bitter, sweet, cold, Rhizoma Curcumae Longae acrid, bitter, warm, after three's compatibility, four gas are gentle, and the five tastes belong to bitter, hardship can restrain, and is beneficial to and slows down tumor growth.Experimental result confirms that anti-hepatocarcinoma and pulmonary carcinoma effect are with the obvious advantage after three compatibility, and non-any three taste Chinese medicine medicine for preventing combinations can reach.
Summary of the invention
The object of the invention is to overcome the deficiencies in the prior art, a kind of Chinese medicine composition to hepatocarcinoma and the high anti-hepatocarcinoma of pulmonary carcinoma suppression ratio and pulmonary carcinoma is provided.
The Chinese medicine composition that second object of the present invention is to provide a kind of anti-hepatocarcinoma and pulmonary carcinoma is in the purposes of the medicine of the anti-hepatocarcinoma of preparation and pulmonary carcinoma.
Technical scheme of the present invention is summarized as follows:
A Chinese medicine composition for anti-hepatocarcinoma and pulmonary carcinoma, comprises Radix Bupleuri extract, Rhizoma Curcumae Longae extract and Rhizoma Anemarrhenae extract that mass ratio is 1 ~ 10:1:1 ~ 10.
The mass ratio of Radix Bupleuri extract, Rhizoma Curcumae Longae extract and Rhizoma Anemarrhenae extract is preferably 5:1:5.
Above-mentioned composition can also comprise the acceptable adjuvant of pharmacy.
The Chinese medicine composition of above-mentioned a kind of anti-hepatocarcinoma and pulmonary carcinoma is in the purposes preparing anti-hepatocarcinoma and lung-cancer medicament.
Preferably, the following method of Radix Bupleuri extract is extracted: Radix Bupleuri was pulverized 40 ~ 50 mesh sieves, is that 75% ~ 85% ethanol water soaks 1 ~ 2 hour by 6 ~ 10 quality times concentration, heating and refluxing extraction 2 ~ 3 times, each 1 ~ 2 hour, filters, merge extractive liquid, leaves standstill 18 ~ 24 hours, centrifugal 3 ~ 10 minutes of 4000 ~ 8000rpm, get supernatant, concentrated, lyophilization, dry thing is pulverized, cross 100 ~ 200 mesh sieves, obtain Radix Bupleuri extract.
Preferably, the following method of Rhizoma Curcumae Longae extract is extracted: pulverized by Rhizoma Curcumae Longae, with the distilled water immersion 1 ~ 2 hour of 6 ~ 10 quality times, heating and refluxing extraction 2 ~ 3 times, each 2 ~ 3 hours, filters, merge extractive liquid, leaves standstill 18 ~ 24 hours, centrifugal 3 ~ 10 minutes of 4000 ~ 8000rpm, get supernatant, concentrated, dry, dry thing is pulverized, cross 100 ~ 200 mesh sieves, obtain Rhizoma Curcumae Longae extract.
Preferably, the following method of Rhizoma Anemarrhenae extract is extracted: by the Rhizoma Anemarrhenae 5 ~ 10 quality distilled water immersion doubly 1 ~ 2 hour, heating and refluxing extraction 2 ~ 3 times, each 2 ~ 3 hours, filter, merge extractive liquid, leave standstill 18 ~ 24 hours, centrifugal 3 ~ 10 minutes of 4000 ~ 8000rpm, gets supernatant, concentrated, lyophilization, dry thing is pulverized, and crosses 100 ~ 200 mesh sieves, obtains Rhizoma Anemarrhenae extract.
Advantage of the present invention:
Prove that compositions of the present invention has through mtt assay experiment in vitro and suppress A549 lung cancer cell line, LA795 lung cancer cell line and BEL-7402 hepatoma cell strain, HepG2 hepatoma cell strain growth, IC
50reach 20mg/mL (crude drug amount) below; Animal experiment in vivo proves to suppress H22 hepatocarcinoma and S180 Growth of Osteosarcoma, and suppression ratio is respectively 55 ± 2.36%, 53 ± 4.62%.Immune function of mice index (spleen index, thymus index) significantly increases.Can also extend ehrlich ascites tumor (EAC) mice median survival interval, the median survival interval of mice extended to 17.15 ± 0.23 days by 12.91 ± 0.86 days.Explanation toxic and side effects reduces.Each component of compositions of the present invention has synergistic function, not only can grow by Tumor suppression, also can extend the ascites tumor life cycle of animal, quality of making the life better.Chinese medicine composition prescription compatibility of the present invention is reasonable, by pungent, warm Rhizoma Curcumae Longae and the cold and cool property of Radix Bupleuri and the Rhizoma Anemarrhenae.Contained by Rhizoma Curcumae Longae and the Rhizoma Anemarrhenae, polysaccharide component has the effect improving immunity, improves antitumor action on the one hand, reduces toxic and side effects on the other hand, improves immunity.Therefore, three's compatibility can play good antitumor action.
Detailed description of the invention
Below in conjunction with specific embodiment, the present invention is further illustrated.
Embodiment 1 ~ embodiment 9 discloses the extracting method of Radix Bupleuri extract, Rhizoma Curcumae Longae extract and Rhizoma Anemarrhenae extract, be noted that, the disclosing of extracting method of these extracts is to enable those skilled in the art understand the present invention better, but the present invention is not imposed any restrictions, the extract of other method acquisition, what its active component was similar to extract active component disclosed by the invention also may be used for the present invention.
Embodiment 1
The following method of Radix Bupleuri extract is extracted: Radix Bupleuri was pulverized 40 mesh sieves, is that 75% ethanol water soaks 1 hour by 10 quality concentration doubly, heating and refluxing extraction 2 times, each 1 hour, filter, merge extractive liquid, leave standstill 18 hours, centrifugal 10 minutes of 4000rpm, gets supernatant, concentrated, lyophilization, dry thing is pulverized, and crosses 200 mesh sieves, obtains Radix Bupleuri extract.
Embodiment 2
The following method of Radix Bupleuri extract is extracted: Radix Bupleuri was pulverized 40 mesh sieves, is that 85% ethanol water soaks 1.5 hours by 6 quality concentration doubly, heating and refluxing extraction 3 times, each 1.5 hours, filter, merge extractive liquid, leave standstill 24 hours, centrifugal 3 minutes of 8000rpm, gets supernatant, concentrated, lyophilization, dry thing is pulverized, and crosses 100 mesh sieves, obtains Radix Bupleuri extract.
Embodiment 3
The following method of Radix Bupleuri extract is extracted: Radix Bupleuri was pulverized 50 mesh sieves, is that 80% ethanol water soaks 2 hours by 8 quality concentration doubly, heating and refluxing extraction 2 times, each 2 hours, filter, merge extractive liquid, leave standstill 20 hours, centrifugal 7 minutes of 6000rpm, gets supernatant, concentrated, lyophilization, dry thing is pulverized, and crosses 100 mesh sieves, obtains Radix Bupleuri extract.
Embodiment 4
The following method of Rhizoma Curcumae Longae extract is extracted: pulverized by Rhizoma Curcumae Longae, with the distilled water immersion 1.5 hours of 8 quality times, and heating and refluxing extraction 3 times, each 3 hours, filter, merge extractive liquid, leave standstill 20 hours, centrifugal 7 minutes of 6000rpm, gets supernatant, concentrated, dry, dry thing is pulverized, and crosses 100 mesh sieves, obtains Rhizoma Curcumae Longae extract.
Embodiment 5
The following method of Rhizoma Curcumae Longae extract is extracted: pulverized by Rhizoma Curcumae Longae, with the distilled water immersion 1 hour of 10 quality times, and heating and refluxing extraction 3 times, each 2 hours, filter, merge extractive liquid, leave standstill 18 hours, centrifugal 10 minutes of 4000rpm, gets supernatant, concentrated, dry, dry thing is pulverized, and crosses 100 sieves, obtains Rhizoma Curcumae Longae extract.
Embodiment 6
The following method of Rhizoma Curcumae Longae extract is extracted: pulverized by Rhizoma Curcumae Longae, with the distilled water immersion 2 hours of 6 quality times, and heating and refluxing extraction 2 times, each 3 hours, filter, merge extractive liquid, leave standstill 24 hours, centrifugal 3 minutes of 8000rpm, gets supernatant, concentrated, dry, dry thing is pulverized, and crosses 200 sieves, obtains Rhizoma Curcumae Longae extract.
Embodiment 7
The following method of Rhizoma Anemarrhenae extract is extracted: by the Rhizoma Anemarrhenae 5 quality distilled water immersion doubly 2 hours, heating and refluxing extraction 3 times, each 2 hours, filter, merge extractive liquid, leaves standstill 24 hours, centrifugal 3 minutes of 8000rpm, get supernatant, concentrated, lyophilization, dry thing is pulverized, cross 100 mesh sieves, obtain Rhizoma Anemarrhenae extract.
Embodiment 8
The following method of Rhizoma Anemarrhenae extract is extracted: by the Rhizoma Anemarrhenae 8 quality distilled water immersion doubly 1.5 hours, heating and refluxing extraction 2 times, each 3 hours, filter, merge extractive liquid, leaves standstill 22 hours, centrifugal 7 minutes of 6000rpm, get supernatant, concentrated, lyophilization, dry thing is pulverized, cross 100 mesh sieves, obtain Rhizoma Anemarrhenae extract.
Embodiment 9
The following method of Rhizoma Anemarrhenae extract is extracted: by the Rhizoma Anemarrhenae 10 quality distilled water immersion doubly 1 hour, heating and refluxing extraction 2 times, each 2 hours, filter, merge extractive liquid, leaves standstill 18 hours, centrifugal 10 minutes of 4000rpm, get supernatant, concentrated, lyophilization, dry thing is pulverized, cross 200 mesh sieves, obtain Rhizoma Anemarrhenae extract.
Embodiment 10
A Chinese medicine composition for anti-hepatocarcinoma and pulmonary carcinoma, comprises Radix Bupleuri extract (prepared by embodiment 3), Rhizoma Curcumae Longae extract (prepared by embodiment 4) and Rhizoma Anemarrhenae extract (prepared by embodiment 8) that mass ratio is 5:1:5.
Embodiment 11
A Chinese medicine composition for anti-hepatocarcinoma and pulmonary carcinoma, comprises Radix Bupleuri extract (prepared by embodiment 2), Rhizoma Curcumae Longae extract (prepared by embodiment 6) and Rhizoma Anemarrhenae extract (prepared by embodiment 7) that mass ratio is 10:1:1.
Embodiment 12
A Chinese medicine composition for anti-hepatocarcinoma and pulmonary carcinoma, comprises Radix Bupleuri extract (prepared by embodiment 1), Rhizoma Curcumae Longae extract (prepared by embodiment 5) and Rhizoma Anemarrhenae extract (prepared by embodiment 9) that mass ratio is 1:1:10.
Embodiment 13
The test of pesticide effectiveness of the Chinese medicine composition of a kind of anti-hepatocarcinoma of the present invention and pulmonary carcinoma:
One. anti-tumor activity test method
1. anti tumor activity in vitro test
BEL-7402 hepatoma cell strain, is incubated at containing 10% inactivated fetal bovine serum, in the RPMI-1640 culture medium of 100U/mL penicillin and 100 μ g/mL streptomycins, in 37 DEG C, and 5%CO
2cultivate under incubator and saturated humidity condition, within 3 ~ 4 days, go down to posterity once.
HepG2 hepatoma cell strain, is incubated at containing 10% inactivated fetal bovine serum, in the DMEM culture medium of 100U/mL penicillin and 100 μ g/mL streptomycins, in 37 DEG C, and 5%CO
2cultivate under incubator and saturated humidity condition, within 3 ~ 4 days, go down to posterity once.
Human pulmonary epithelial cells strain, is incubated at containing 10% inactivated fetal bovine serum, in the DMEM culture medium of 100U/mL penicillin and 100 μ g/mL streptomycins, in 37 DEG C, and 5%CO
2cultivate under incubator and saturated humidity condition, within 3 ~ 4 days, go down to posterity once.
Mouse pulmonary adenocarcinoma cell line LA 795 strain, is incubated at containing 10% inactivated fetal bovine serum, in the RPMI-1640 culture medium of 100U/mL penicillin and 100 μ g/mL streptomycins, in 37 DEG C, and 5%CO
2cultivate under incubator and saturated humidity condition, within 3 ~ 4 days, go down to posterity once.
Mtt assay: be 3 × 10 by being mixed with concentration after the trypsinization of exponential phase cell
4the cell suspension of individual/mL, is inoculated in 96 hole ELISA Plate, and every hole adds 200 μ L.Change after 24h and containing serum free culture system liquid, cell synchronization is grown, every hole 200 μ L.Within 3rd day, add by reagent in hole, namely Radix Bupleuri extract (prepared by embodiment 3) aqueous solution is added respectively, Rhizoma Curcumae Longae extract (prepared by embodiment 4) aqueous solution and Rhizoma Anemarrhenae extract (prepared by embodiment 8) aqueous solution, the composition solution of embodiment 10, embodiment 11, embodiment 12 preparation; Separately establish matched group: 0.1% dimethyl sulfoxide (DMSO), every hole adds 200 μ L.Often organize by reagent and establish 0.01 respectively, 0.1,1,10,100,1000 μ g/mL, six concentration, each concentration establishes 8 parallel holes, and cultivate 24h at 37 DEG C after, every hole adds serum-free without phenol red culture fluid freshly prepared 0.5mg/mL MTT 100 μ L, continue to cultivate 4h, then, every hole adds 100 μ L DMSO and dissolves MTT formazan granule, after microoscillator vibration mixing, microplate reader measures optical density value (OD), and experiment in triplicate, is averaged.With solvent control process tumor cell for matched group, suppression ratio is calculated by OD value, formula is: inhibitory rate of cell growth=(matched group OD value-experimental group OD value)/matched group OD × 100%, and be abscissa with drug level, OD value is vertical coordinate, draw cell growth curve, and try to achieve IC
50(half suppression ratio), IC
50(crude drug amount)=inhibitory rate of cell growth is the drug level of 50%.The results are shown in Table 1.
Table 1 anti tumor activity in vitro result of the test
2. anti-tumor in vivo activity test
2.1H
22liver cancer model is tested
2.1.1 animal model
With 140 kunming mices (female, 18 ~ 20g), mice H is carried out to compositions of the present invention
22the test of pesticide effectiveness in liver cancer model body.
Get inoculation H
22hepatoma carcinoma cell is the well-grown tumor-bearing mice of ascites after 6 ~ 8 days, sterilization abdominal part, in superclean bench, extract milky ascites is tumor source, get ascites 10mL, by ascites with normal saline in proportion for 1:1 mixes, be made into cell suspension, extract 0.1mL, under being inoculated in every kunming mice right fore axillary fossa with asepsis injector.Whole operation is aseptically carried out.2.1.2 animal grouping and administration
H will be inoculated
22140 kunming mices of hepatoma carcinoma cell are divided into 14 groups, often organize 10.Inoculate and start administration, every day 1 time next day: (1) model group, gavages normal saline, every 0.2mL; (2) chemotherapy group: by 20mg/kgbw intraperitoneal injection of cyclophosphamide; (3) Radix Bupleuri extract (prepared by embodiment 3) high dose group: gavage Radix Bupleuri extract 0.2mL by 6g (crude drug amount)/kgbw; (4) Radix Bupleuri extract (prepared by embodiment 3) low dose group: gavage Radix Bupleuri extract 0.2mL by 3g (crude drug amount)/kgbw; (5) Rhizoma Curcumae Longae extract (prepared by embodiment 4) high dose group: gavage Rhizoma Curcumae Longae extract 0.2mL by 6g (crude drug amount)/kgbw; (6) Rhizoma Curcumae Longae extract (prepared by embodiment 4) low dose group: gavage Rhizoma Curcumae Longae extract 0.2mL by 3g (crude drug amount)/kgbw; (7) Rhizoma Anemarrhenae extract (prepared by embodiment 8) high dose group: gavage Rhizoma Anemarrhenae extract 0.2mL by 6g (crude drug amount)/kgbw; (8) Rhizoma Anemarrhenae extract (prepared by embodiment 8) low dose group: gavage Rhizoma Anemarrhenae extract 0.2mL by 3g (crude drug amount)/kgbw; (9) embodiment 10 high dose group: by 6g (crude drug amount)/kgbw drench composition 0.2mL; (10) embodiment 10 low dose group: by 3g (crude drug amount)/kgbw drench composition 0.2mL; (11) embodiment 11 high dose group: by 6g (crude drug amount)/kgbw drench composition 0.2mL; (12) embodiment 11 low dose group: by 3g (crude drug amount)/kgbw drench composition 0.2mL; (13) embodiment 12 high dose group: by 6g (crude drug amount)/kgbw drench composition 0.2mL; (14) embodiment 12 low dose group: by 3g (crude drug amount)/kgbw drench composition 0.2mL; Two weeks, terminate rear cervical dislocation execution next day mice in administration, solution takes its tumor tissue, wins spleen, and thymus is also weighed.Survey tumour inhibiting rate: (i) tumour inhibiting rate (%)=(the average tumor weight of 1-administration group average tumor weight/model group) × 100%, win spleen, thymus, and weigh.Spleen index=(spleen weight/body weight) * 1000, thymus index=(thymic weight/body weight) * 1000, the results are shown in Table 2 and table 3.
Table 2 H
22hepatocarcinoma tumor-bearing mice tumour inhibiting rate experimental result
Table 3 H
22hepatocarcinoma tumor-bearing mice Immune Organs Index
Note: compare with model group, * P<0.05, * * P<0.01
The model experiment of 2.2S180 osteosarcoma
2.2.1 animal model
With 140 kunming mices (female, 18 ~ 20g), the test of pesticide effectiveness in mice S180 osteosarcoma model body is carried out to compositions of the present invention.
Get inoculation S180 osteosarcoma cell well-grown tumor-bearing mice of ascites after 6 ~ 8 days, sterilization abdominal part, in superclean bench, extract milky ascites is tumor source, get ascites 10mL, by ascites with normal saline in proportion for 1:1 mixes, be made into cell suspension, extract 0.1mL, under being inoculated in every kunming mice right fore axillary fossa with asepsis injector.Whole operation is aseptically carried out.
2.2.2 animal grouping and administration
140 kunming mices of inoculation S180 osteosarcoma cell are divided into 14 groups, often organize 10.Inoculate and start administration, every day 1 time next day: (1) model group, gavages normal saline, every 0.2mL; (2) chemotherapy group: by 20mg/kgbw intraperitoneal injection of cyclophosphamide; (3) Radix Bupleuri extract (prepared by embodiment 3) high dose group: gavage Radix Bupleuri extract 0.2mL by 6g (crude drug amount)/kgbw; (4) Radix Bupleuri extract (prepared by embodiment 3) low dose group: gavage Radix Bupleuri extract 0.2mL by 3g (crude drug amount)/kgbw; (5) Rhizoma Curcumae Longae extract (prepared by embodiment 4) high dose group: gavage Rhizoma Curcumae Longae extract 0.2mL by 6g (crude drug amount)/kgbw; (6) Rhizoma Curcumae Longae extract (prepared by embodiment 4) low dose group: gavage Rhizoma Curcumae Longae extract 0.2mL by 3g (crude drug amount)/kgbw; (7) Rhizoma Anemarrhenae extract (prepared by embodiment 8) high dose group: gavage Rhizoma Anemarrhenae extract 0.2mL by 6g (crude drug amount)/kgbw; (8) Rhizoma Anemarrhenae extract (prepared by embodiment 8) low dose group: gavage Rhizoma Anemarrhenae extract 0.2mL by 3g (crude drug amount)/kgbw; (9) embodiment 10 high dose group: by 6g (crude drug amount)/kgbw drench composition 0.2mL; (10) embodiment 10 low dose group: by 3g (crude drug amount)/kgbw drench composition 0.2mL; (11) embodiment 11 high dose group: by 6g (crude drug amount)/kgbw drench composition 0.2mL; (12) embodiment 11 low dose group: by 3g (crude drug amount)/kgbw drench composition 0.2mL; (13) embodiment 12 high dose group: by 6g (crude drug amount)/kgbw drench composition 0.2mL; (14) embodiment 12 low dose group: by 3g (crude drug amount)/kgbw drench composition 0.2mL; Two weeks, terminate rear cervical dislocation execution next day mice in administration, solution takes its tumor tissue, wins spleen, and thymus is also weighed.Survey tumour inhibiting rate: (i) tumour inhibiting rate (%)=(the average tumor weight of 1-administration group average tumor weight/model group) × 100%, win spleen, thymus, and weigh.Spleen index=(spleen weight/body weight) * 1000, thymus index=(thymic weight/body weight) * 1000, the results are shown in Table 4 and table 5.
Table 4 S180 osteosarcoma tumor-bearing mice tumour inhibiting rate experimental result
Table 5 S180 osteosarcoma tumor-bearing mice Immune Organs Index
Note: compare with model group, * P<0.05, * * P<0.01
2.3EAC model test
2.2.1 animal model
With 140 kunming mices (female, 18 ~ 20g), the test of pesticide effectiveness in mice EAC model body is carried out to compositions of the present invention.
Get inoculation EAC cell well-grown tumor-bearing mice of ascites after 6 ~ 8 days, sterilization abdominal part, in superclean bench, extract milky ascites is tumor source, gets ascites 15mL, by ascites with normal saline in proportion for 1:1 mixes, be made into cell suspension.Cell suspension is extracted, every mouse peritoneal injection 0.2ml with asepsis injector.Whole operation is aseptically carried out.
2.2.2 animal grouping and administration
140 kunming mices of inoculation EAC cell are divided into 14 groups, often organize 10.Inoculate and start administration, every day 1 time next day: (1) model group, gavages normal saline, every 0.2mL; (2) chemotherapy group: by 20mg/kgbw lumbar injection cisplatin; (3) Radix Bupleuri extract (prepared by embodiment 3) high dose group: gavage Radix Bupleuri extract 0.2mL by 6g (crude drug amount)/kgbw; (4) Radix Bupleuri extract (prepared by embodiment 3) low dose group: gavage Radix Bupleuri extract 0.2mL by 3g (crude drug amount)/kgbw; (5) Rhizoma Curcumae Longae extract (prepared by embodiment 4) high dose group: gavage Rhizoma Curcumae Longae extract 0.2mL by 6g (crude drug amount)/kgbw; (6) Rhizoma Curcumae Longae extract (prepared by embodiment 4) low dose group: gavage Rhizoma Curcumae Longae extract 0.2mL by 3g (crude drug amount)/kgbw; (7) Rhizoma Anemarrhenae extract (prepared by embodiment 8) high dose group: gavage Rhizoma Anemarrhenae extract 0.2mL by 6g (crude drug amount)/kgbw; (8) Rhizoma Anemarrhenae extract (prepared by embodiment 8) low dose group: gavage Rhizoma Anemarrhenae extract 0.2mL by 3g (crude drug amount)/kgbw; (9) embodiment 10 high dose group: by 6g (crude drug amount)/kgbw drench composition 0.2mL; (10) embodiment 10 low dose group: by 3g (crude drug amount)/kgbw drench composition 0.2mL; (11) embodiment 11 high dose group: by 6g (crude drug amount)/kgbw drench composition 0.2mL; (12) embodiment 11 low dose group: by 3g (crude drug amount)/kgbw drench composition 0.2mL; (13) embodiment 12 high dose group: by 6g (crude drug amount)/kgbw drench composition 0.2mL; (14) embodiment 12 low dose group: by 3g (crude drug amount)/kgbw drench composition 0.2mL; The death time of experimental session record every mice, finally calculate median survival interval and mean survival time (MST).The results are shown in Table 6
Table 6 EAC extends experimental result life cycle
Note: compare with model group, * P<0.05, * * P<0.01
Add in compositions of the present invention the acceptable adjuvant of pharmacy as: starch, dextrin, Icing Sugar, lactose, rubber cement, Polyethylene Glycol, sodium carboxymethyl cellulose etc., be prepared into tablet, capsule, granule, watered pill, drop pill etc. according to a conventional method.
Above data combine in body and experiment in vitro, and experiment in vivo has been investigated again compositions and suppressed implanted solid tumor growth, extends Animals with ascitic tumors life cycle and animal immune shoot formation.The overall merit effect of Chinese medicine composition of the present invention in anti-hepatocarcinoma and pulmonary carcinoma.
Claims (4)
1. a Chinese medicine composition for anti-hepatocarcinoma and pulmonary carcinoma, its feature comprises Radix Bupleuri extract, Rhizoma Curcumae Longae extract and the Rhizoma Anemarrhenae extract that mass ratio is 1 ~ 10:1:1 ~ 10.
2. the Chinese medicine composition of a kind of anti-hepatocarcinoma according to claim 1 and pulmonary carcinoma, is characterized in that the mass ratio of described Radix Bupleuri extract, Rhizoma Curcumae Longae extract and Rhizoma Anemarrhenae extract is 5:1:5.
3. the Chinese medicine composition of a kind of anti-hepatocarcinoma according to claim 1 and 2 and pulmonary carcinoma, its feature also comprises the acceptable adjuvant of pharmacy.
4. a kind of anti-hepatocarcinoma of one of claims 1 to 3 and the Chinese medicine composition of pulmonary carcinoma are in the purposes preparing anti-hepatocarcinoma and lung-cancer medicament.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510088489.7A CN104707101B (en) | 2015-02-26 | 2015-02-26 | A kind of Traditional Chinese medicinal composition for treating lung cancer and liver cancer and purposes |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510088489.7A CN104707101B (en) | 2015-02-26 | 2015-02-26 | A kind of Traditional Chinese medicinal composition for treating lung cancer and liver cancer and purposes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104707101A true CN104707101A (en) | 2015-06-17 |
| CN104707101B CN104707101B (en) | 2018-05-04 |
Family
ID=53407145
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510088489.7A Expired - Fee Related CN104707101B (en) | 2015-02-26 | 2015-02-26 | A kind of Traditional Chinese medicinal composition for treating lung cancer and liver cancer and purposes |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104707101B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108079249A (en) * | 2017-12-28 | 2018-05-29 | 晨光生物科技集团邯郸有限公司 | A kind of Chinese medicine preparation with liver protection and preparation method thereof |
| CN109432355A (en) * | 2018-11-30 | 2019-03-08 | 佛山科学技术学院 | A kind of Chinese medicine composition of anti-liver cancer and anti-and preparation method thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101049484A (en) * | 2007-05-14 | 2007-10-10 | 郝来勤 | Strong effective Chinese traditional medicine for treating lung cancer and other various cancers |
| CN101773636A (en) * | 2009-01-09 | 2010-07-14 | 苏州知微堂生物科技有限公司 | Antitumor nanometer Chinese medicine and production method thereof |
| CN104043057A (en) * | 2014-06-28 | 2014-09-17 | 王星月 | Traditional Chinese medicinal composition for treating lymph cancer |
-
2015
- 2015-02-26 CN CN201510088489.7A patent/CN104707101B/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101049484A (en) * | 2007-05-14 | 2007-10-10 | 郝来勤 | Strong effective Chinese traditional medicine for treating lung cancer and other various cancers |
| CN101773636A (en) * | 2009-01-09 | 2010-07-14 | 苏州知微堂生物科技有限公司 | Antitumor nanometer Chinese medicine and production method thereof |
| CN104043057A (en) * | 2014-06-28 | 2014-09-17 | 王星月 | Traditional Chinese medicinal composition for treating lymph cancer |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108079249A (en) * | 2017-12-28 | 2018-05-29 | 晨光生物科技集团邯郸有限公司 | A kind of Chinese medicine preparation with liver protection and preparation method thereof |
| CN109432355A (en) * | 2018-11-30 | 2019-03-08 | 佛山科学技术学院 | A kind of Chinese medicine composition of anti-liver cancer and anti-and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104707101B (en) | 2018-05-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102166335A (en) | Ginger and long pepper composition as well as preparation method and application thereof in preparation of toxicity reducing and efficacy enhancing medicament in radiotherapy and chemotherapy of cancer | |
| Zhao et al. | Polygonati Rhizoma with the homology of medicine and food: A review of ethnopharmacology, botany, phytochemistry, pharmacology and applications | |
| CN104013668A (en) | Application of licoflavone extract in preparation of medicine for treating ulcerative colitis | |
| CN104436018B (en) | Treat medicine of tumour and preparation method thereof | |
| CN112336815A (en) | Anti-aging composition for strengthening body, preventing cancer and conditioning hypertension, hyperglycemia and hyperlipidemia and application thereof | |
| CN102114099B (en) | Traditional Chinese medicine preparation for inhibiting liver cancer and preparation method thereof | |
| CN103479963A (en) | Traditional Chinese medicine capsules for treating rheumatoid arthritis and preparation method thereof | |
| CN105327071A (en) | Antineoplastic traditional Chinese medicinal composition and application thereof | |
| CN104707101B (en) | A kind of Traditional Chinese medicinal composition for treating lung cancer and liver cancer and purposes | |
| CN102247479A (en) | Antitumor strong medicine and preparation method thereof | |
| CN101564466A (en) | Traditional Chinese medicine effective part composition containing antineoplastic active ingredients as well as preparation method and application thereof | |
| CN103142934B (en) | Traditional Chinese medicinal composition for treating lung cancer and liver cancer | |
| CN103933541B (en) | A kind of glutathion anti-cancer composition | |
| CN102225089B (en) | Pharmaceutical composition for treating cancers, pharmaceutical preparation as well as applications and production methods thereof | |
| CN103933472B (en) | A kind of Traditional Chinese medicinal composition for treating lung cancer and liver cancer | |
| CN102091312B (en) | Ginger and wild pepper composition and preparation method thereof, and application of ginger and wild pepper composition in preparation of attenuation and synergy medicaments for radiotherapy and chemotherapy of cancers | |
| CN103169844B (en) | Traditional Chinese medicine composition having anti-lung cancer and anti-liver cancer effects | |
| CN103142935A (en) | Traditional Chinese medicinal composition for treating lung cancer and liver cancer | |
| CN102114065B (en) | Longhairy antenoron herb and common threewingnut root Chinese medicinal composition with effect of preventing and treating cancer and application thereof | |
| CN102379973B (en) | Preparation method and application of effective part of solanaceae physalis plant | |
| CN100411663C (en) | Anticancer compound Chinese medicine powder and its preparing method | |
| CN103169845B (en) | Traditional Chinese medicine composition having anti-liver cancer and anti-lung cancer effects | |
| CN103585243B (en) | A kind of Solms-Laubachia extract is preparing the application in cancer therapy drug | |
| CN103263492A (en) | Traditional chinese medicine extract | |
| CN101284052B (en) | Chinese medicinal materials compound prescription for treating the tumor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20180504 Termination date: 20200226 |